ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XERS vs SLS // ALTMAN Z-SCORE & DEBT/EQUITY

Xeris Biopharma Holdings Inc. (NASDAQ) VS. SELLAS Life Sciences Group Inc. (NASDAQ) • 15-METRIC TALLY: XERS 4 — SLS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. SLS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XERS SLS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 16.00% -21.80% +37.80 XERS /roic <GO>
EV/EBITDA & P/E Valuation 83.1x — — TIE /valuation <GO>
Free Cash Flow Yield 1.46% -1.38% +2.84 XERS /fcf-yield <GO>
Operating Margin 8.50% — — TIE /operating-margins <GO>
Net Profit Margin 0.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 43.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 2.11 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 XERS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.7 39.8 +19.90 XERS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.95B $1.95B -$2.2M SLS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XERS REV SLS REV XERS GROSS % SLS GROSS % XERS FCF SLS FCF
FY 2025 $291.8M $79.2M — — $28.6M -$28.4M
FY 2024 $203.1M $88.2M — — -$37.0M -$35.4M
FY 2023 $163.9M $106.0M — — -$47.0M -$31.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
SLS // BETA —